Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an update on its ongoing Phase 1/2 open-label clinical trial evaluating NGN-401 gene therapy for the treatment...
2024-11-11 NeuroGene的NGN-401临床试验中期数据发布会 Part 6:问答环节 156 -- 28:44 App 2024-03-20 NeuroGene Stifel 2024 Virtual CNS Days 165 -- 24:14 App 2022-11-17 Taysha Video Update on its Rett Syndrome Clinical Trial wSub 20 -- 31:12 App 2021-02-25 Anavex SVB Leerink HC ...